Utah Medical Products Reports 2025 Earnings Decline, Projects 2026 EPS Growth Amidst Strategic Shifts

summarizeSummary

Utah Medical Products reported a 5.8% revenue decrease and an 18.7% net income decline for 2025, primarily due to lost OEM sales and one-time charges. However, the company maintains a strong cash position and projects a 15-18% increase in 2026 operating income and EPS above $4.00, driven by reduced amortization and litigation expenses.

check_boxKey Events

• 2025 Financial Performance

  Net sales decreased by 5.8% to $38.5 million, and net income fell by 18.7% to $11.3 million, resulting in diluted EPS of $3.48.

• Revenue Decline Drivers

  The decrease was primarily attributed to a $2.3 million drop in OEM sales to PendoTECH and a $0.3 million reduction from a China distributor, along with a $0.7 million decline in Filshie Clip System sales.

• One-Time Expenses Impacting 2025

  2025 results included a $0.4 million bad debt write-off from the China distributor and a $0.2 million loss from embezzlement in Australia.

• Strong Liquidity & Shareholder Returns

  The company ended 2025 with $85.8 million in cash, increased its current ratio, and continued to return capital through $8.4 million in share repurchases and $4.0 million in dividends.

auto_awesomeAnalysis

Utah Medical Products faced a challenging 2025 with a notable decline in revenue and net income, largely due to the cessation of significant OEM contracts and one-time financial hits. However, the company's robust cash reserves and ongoing commitment to shareholder returns through dividends and share repurchases highlight its financial stability. The forward guidance for 2026 is optimistic, projecting a rebound in profitability driven by the winding down of substantial amortization expenses and a reduction in litigation costs. Investors should monitor the company's ability to offset lost OEM revenues with new product sales and the final resolution of the remaining Filshie clip lawsuits.